3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
7
Melanoma
7
Lung Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Rectal Neoplasms
3
Head and Neck Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Neoplasm, Residual
2
Hyperthermia
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Radiation Pneumonitis
1
Interventions
atezolizumab
2
Sorafenib
2
Bevacizumab
2
titanium silicide
1
ledipasvir, sofosbuvir drug combination
1
halofantrine
1
genexol-PM
1
durvalumab
1
avatrombopag
1
aumolertinib
1
Sunitinib
1
Ramucirumab
1
Neoadjuvant Therapy
1
N-monoacetylcystine
1
Leucovorin
1
Injections
1
Immunotherapy
1
Formyltetrahydrofolates
1
Everolimus
1
Cisplatin
1
Catheter Ablation
1
Adjuvants, Pharmaceutic
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liver Diseases
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled